Vanguard Global Advisers’s Regenxbio RGNX Stock Holding History

Vanguard Global Advisers’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$223K	Hold	18,588	–	–	﹤0.01%	2460
2026 Q1	$156K	Buy	+18,588	New	+$195K	﹤0.01%	2549

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Global Advisers's RGNX Position: Q2 2026 in Review

Vanguard Global Advisers held its Regenxbio (RGNX) position steady in Q2 2026 at 18,588 shares worth $223K. The position accounts for ﹤0.01% of the portfolio, ranked #2460.

Vanguard Global Advisers first reported a position in RGNX in Q1 2026 and has held it in 2 quarters since. 164 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

Vanguard Global Advisers held 18,588 shares of Regenxbio worth $223K as of Q2 2026.
Vanguard Global Advisers left its Regenxbio share count unchanged in Q2 2026.
Regenxbio made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2460 holding.
Vanguard Global Advisers first reported a position in Regenxbio in Q1 2026 and has held it in 2 quarters since.
164 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.